Unusual colours of plasma
Expression of multiple cytokines and CCR4 in primary testicular diffuse large B-cell lymphoma, not otherwise specified, involving the skin
Current strategies in the diagnosis of diffuse large B-cell lymphoma of the central nervous system
Biomarkers in sickle cell disease
Guidelines on the investigation and management of follicular lymphoma
Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status – consequences and potentials for pharmacological intervention
An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients
Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma
Defining the prognosis of early stage chronic lymphocytic leukaemia patients
Platelet apoptosis in paediatric immune thrombocytopenia is ameliorated by intravenous immunoglobulin
Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure
Regulation of fas/fas ligand-mediated apoptosis by nuclear factor of activated T cells in megakaryocytes
Mouse models for studying pain in sickle disease: effects of strain, age, and acuteness
Red cells exchanges in sickle cells disease lead to a selective reduction of erythrocytes-derived blood microparticles
The eukaryotic Initiating Factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia
Alpha interferon augments the graft-versus-leukaemia effect of second stem cell transplants and donor lymphocyte infusions in high-risk paediatric leukaemias
Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma
Bendamustine, thalidomide and dexamethasone is an effective salvage regimen for advanced stage multiple myeloma – response to Grey-Davies et al